glp-1 receptor agonist and dpp-4 inhibitor combination not recommended Comparison of agonists inhibitors GLP-1 receptor agonists vs. DPP-4
Description
[DOI] [PubMed] [Google Scholar] 48
The compound annual growth rate (CAGR) for the period 2020-2024 stood at 10.46%
The ongoing dedicated ophthalmic trial named as FOCUS study, which aims to evaluate semaglutides long-term effects on diabetic retinopathy, is now ongoing and could contribute to a comprehensive understanding of the true risk-benefit profile of these agents in patients with or at risk for diabetic retinopathy (NCT03811561) [104]
Diarrhea affects about 30% of users of both medications
& Russell-Jones, D
doi: 10.1007/s40265-014-0321-6 183 ChalasaniNYounossiZLavineJECharltonMCusiKRinellaMet al
